VivoSeq
Oncology

Acute Myeloid Leukaemia

7

Pipeline Programs↗

2

Active Trials↗

8

Companies Involved↗

Acute Myeloid Leukaemia is an early-stage landscape with 7 programs across 8 companies. The most active players are Sanofi, EMD Serono, Teva. 7 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

89/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

2 programs

Phase 3EMD Serono logo

EMD Serono

1 program

Phase 3Teva logo

Teva

1 program

Phase 3Akero Therapeutics logo

Akero Therapeutics

1 program

Phase 3Boehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalI

Innate Pharma

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 37

Gemtuzumab Ozogamicin

Wyeth-Lederle Vaccines

Liposomal Daunorubicin

Sanofi

Mitoxantrone

EMD Serono

Fludarabine

Sanofi

Cytarabine

Teva

Approved
No programs

Analysis

Modality Breakdown

86%

Small molecule

6 of 7 classified programs — the dominant modality here.

14%ALL OTHERSAntibody–drug conjugate114%

Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 100% of 7 pipeline programs.

Analysis

Trial Status

17

clinical trials

Completed8 · 47%
Unknown status6 · 35%
Withdrawn1 · 6%
Recruiting1 · 6%
Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

17 trials

Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia
Recruiting·—·Phase 1·NCT06326021·27 enrolled
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy
Active, not recruiting·UUniversity of Birmingham·Phase 3·NCT02724163·700 enrolled
BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT00701766·71 enrolled
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
Completed·HHospital Universitario 12 de Octubre·Phase 1·NCT03197714·9 enrolled
Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT00804856·180 enrolled
Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide
Completed·TTehran University of Medical Sciences·Phase 2·NCT00850304·10 enrolled
A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia
Completed·IInnate Pharma·Phase 1·NCT01256073·21 enrolled
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
Completed·CClavis Pharma·Phase 2·NCT01035502·51 enrolled
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT01721876·666 enrolled
Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia
Completed·Institut de Recherches Internationales Servier logoInstitut de Recherches Internationales Servier·Phase 1/2·NCT04629443·17 enrolled
A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed
Withdrawn·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT02722135
Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2
Unknown status·KKing's College Hospital NHS Trust·Phase 1·NCT00718250·24 enrolled
Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years
Unknown status·—·Phase 3·NCT01828489·300 enrolled
Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia
Unknown status·MMendus·Phase 2·NCT03697707·20 enrolled
Ex-vivo Expanded γδ T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid Leukaemia
Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT04008381·38 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)